Treatment of Fanconi Anemia with Severe Bone Marrow Failure or Aplastic Anemia (Hgb <8 g/dL)
This protocol addresses Fanconi anemia patients who have progressed to severe bone marrow failure, myelodysplastic syndrome (MDS), or acute myeloid leukemia (AML) and who meet specific eligibility criteria for definitive intervention.
Clinical scenario
Applies when one or more of the following is present:
- Aplastic anemia: hemoglobin <8 g/dL, absolute neutrophil count <500/µL, or platelet count <20,000/µL
- Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
- Progressive complex cytogenetic abnormalities associated with malignancy
Patient eligibility requires absence of active infections, adequate organ function, age under 35 years, and no severe organ dysfunction or pre-existing malignancy.
Treatment approach
Hematopoietic cell transplant (HCT) is the only curative treatment for bone marrow failure in Fanconi anemia. The approach involves careful donor selection according to match priority, with the conditioning regimen and GVHD prophylaxis strategy determined by the donor type available. The complete structured regimen is in the full protocol.
References
- Aplastic anemia (hemoglobin (Hgb) <8 g/dL or absolute neutrophil count (ANC) <500/uL or platelet count <20,000/uL)
- MDS or AML
- Progressive complex cytogenetic abnormalities known to be associated with malignancy
- Patients with FA who develop persistent and severe cytopenias or evidence of MDS or AML should be considered for HCT provided the patient is not too old and has adequate organ function.
- Patients with an exceptional risk of HCT-related mortality (e.g., patients with severe organ dysfunction, those who are 35 years or older, and those with pre-existing malignancies or life-threatening systemic infections) may consider alternative treatment options first, such as the use of androgens.
- The only curative option for bone marrow failure (BMF) in patients with FA is a hematopoietic cell transplant (HCT).
- HLA 10/10 (followed by 9/10) allele-matched sibling
- HLA 10/10 (followed by 9/10) allele-matched relative other than sibling
- HLA 10/10 (followed by 9/10) allele-matched unrelated adult volunteer
- HLA 10-8/10 antigen matched UCB
View source ↗